ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Spherix Global Insights

< Previous 1 2 3 4 5 6 Next >

Spherix Global Insights Builds on Respiratory Research Portfolio to Support Continued Growth and Broader Indication Coverage

September 21, 2026

From Spherix Global Insights

Via GlobeNewswire

Dupixent, Skyrizi, Tremfya, Keytruda, Darzalex, and Hemlibra Among Patient Support Leaders as New Spherix Global Insights Research Reveals What Sets Top Programs Apart

September 14, 2026

From Spherix Global Insights

Via GlobeNewswire

Spherix Global Insights Research Reveals a CKD Symptom Disconnect: 86% of Patients Report Symptoms While Nephrologists Classify Nearly Half as Asymptomatic

September 11, 2026

From Spherix Global Insights

Via GlobeNewswire

Japanese Gastroenterologists Support Earlier Advanced Therapy in Ulcerative Colitis, but Practice Lags Behind Belief, Spherix Global Insights Finds

September 11, 2026

From Spherix Global Insights

Via GlobeNewswire

Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline Innovation

September 10, 2026

From Spherix Global Insights

Via GlobeNewswire

Earlier Intervention Reshapes the Multiple Myeloma Treatment Continuum as Advanced Therapy Options Expand, According to Spherix Global Insights

September 10, 2026

From Spherix Global Insights

Via GlobeNewswire

COPD Treatment Landscape Expands, Yet Significant Gaps in Disease Control and Access Persist, According to Spherix Global Insights

September 08, 2026

From Spherix Global Insights

Via GlobeNewswire

Nearly two-thirds of Nephrologists Cite Limited Treatment Options as Alport Syndrome’s Greatest Challenge Amid Growing Pipeline Interest, According to Spherix Global Insights

August 31, 2026

From Spherix Global Insights

Via GlobeNewswire

Neurologists Interested in Cell Therapy in Neuro-Immune Diseases, but Safety and Logistics Will Shape Adoption, According to Spherix Global Insights

August 25, 2026

From Spherix Global Insights

Via GlobeNewswire

As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene Therapy

August 25, 2026

From Spherix Global Insights

Via GlobeNewswire

Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands

August 20, 2026

From Spherix Global Insights

Via GlobeNewswire

Bimzelx Momentum Builds as Rheumatologists Look Beyond TNFs to the Next Wave of axSpA Therapies, According to Spherix Global Insights

August 19, 2026

From Spherix Global Insights

Via GlobeNewswire

Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success

August 13, 2026

From Spherix Global Insights

Via GlobeNewswire

IL-23 Inhibitors Gain Physician Preference for IBD Across Europe, Yet Actual Use Continues to Lag, According to Spherix Global Insights

August 13, 2026

From Spherix Global Insights

Via GlobeNewswire

Spherix Global Insights Launches RapidPulse Dynamix™ to Support Time-Sensitive Market Insights

August 04, 2026

From Spherix Global Insights

Via GlobeNewswire

New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff

July 29, 2026

From Spherix Global Insights

Via GlobeNewswire

Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights

July 24, 2026

From Spherix Global Insights

Via GlobeNewswire

Sotyktu Begins Defining a New Oral Treatment Segment in Psoriatic Arthritis, According to Spherix Global Insights Launch Research

July 23, 2026

From Spherix Global Insights

Via GlobeNewswire

Spherix Global Insights Reports Persistent High Unmet Need in Europe's Evolving MASH Market

July 08, 2026

From Spherix Global Insights

Via GlobeNewswire

Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain

July 07, 2026

From Spherix Global Insights

Via GlobeNewswire

CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need

June 17, 2026

From Spherix Global Insights

Via GlobeNewswire

Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026

June 12, 2026

From Spherix Global Insights

Via GlobeNewswire

Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies

May 28, 2026

From Spherix Global Insights

Via GlobeNewswire

Eli Lilly’s Oral GLP-1 Foundayo Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights

May 27, 2026

From Spherix Global Insights

Via GlobeNewswire

Real-World CAR-T Delays in LBCL Drive Reliance on Bridging Therapy, According to Spherix Global Insights

May 21, 2026

From Spherix Global Insights

Via GlobeNewswire

Sotyktu’s Psoriatic Arthritis Launch Builds Gradually in Month Two as Rheumatologists Continue to Take Measured Approach to TYK2 Adoption, According to Spherix Global Insights

May 19, 2026

From Spherix Global Insights

Via GlobeNewswire

SGLT2 Inhibitors Entrenched as Foundational CKD Therapy While GLP-1 Adoption Remains Selective, According to Spherix Global Insights

May 13, 2026

From Spherix Global Insights

Via GlobeNewswire

Lupus Patients Continue to Navigate Delayed Diagnosis, High Disease Burden, and Complex Treatment Journeys, According to Spherix Global Insights

May 05, 2026

From Spherix Global Insights

Via GlobeNewswire

Spherix Advances Oncology Leadership with Novel PD-1 Findings and Inaugural Presence at American Society of Clinical Oncology (ASCO) Annual Meeting 2026

April 29, 2026

From Spherix Global Insights

Via GlobeNewswire

Spherix Global Insights Finds Specialty Split in Perceptions of Direct-to-Patient Platforms for Obesity Treatment

April 24, 2026

From Spherix Global Insights

Via GlobeNewswire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.